Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ERIC CLL 2026 | BRUIN CLL-322 update: fixed-duration pirtobrutinib plus venetoclax-rituximab in R/R CLL

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, shares updated data from the BRUIN CLL-322 trial (NCT04965493), which showed that fixed-duration pirtobrutinib plus venetoclax and rituximab (PVR) outperformed venetoclax plus rituximab (VR) in relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Dr Davids highlights that the pirtobrutinib combination did not add significant additional toxicity and is becoming a potential new standard of care, although its efficacy in patients progressing after frontline venetoclax-based therapy remains an extrapolation. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So we presented this data at the 2026 EHA meeting in the late abstract session and also published this in the Lancet and the dataset I think really looks convincing that pirtobrutinib when given with venetoclax and rituximab is superior to the venetoclax rituximab standard of care for relapsed/refractory CLL. There’s a significant progression-free survival advantage even in the early interim analysis, and particularly the benefit was observed for patients who had previously been treated with a BTK inhibitor, especially if they’d actually progressed on a prior covalent BTK inhibitor...

So we presented this data at the 2026 EHA meeting in the late abstract session and also published this in the Lancet and the dataset I think really looks convincing that pirtobrutinib when given with venetoclax and rituximab is superior to the venetoclax rituximab standard of care for relapsed/refractory CLL. There’s a significant progression-free survival advantage even in the early interim analysis, and particularly the benefit was observed for patients who had previously been treated with a BTK inhibitor, especially if they’d actually progressed on a prior covalent BTK inhibitor. Those were the patients who really benefited the most from this PVR combination. It’s also important to note that the pirtobrutinib did not add a lot of additional toxicity beyond venetoclax and rituximab alone, and so I think this is becoming now a potential new standard of care. It’s waiting still for registration. But already in the US, we have it listed in our NCCN guidelines and we can get access to it. And I think it’s a great combination for patients, particularly progressing after covalent BTK inhibitors or chemoimmunotherapy in the past. I think a challenge is that the study did not include patients progressing after frontline venetoclax-based therapy. So it’s a bit of an extrapolation to use it in that population, although I think it still would be active. So I think the VR arm of the CLL-322 trial is particularly interesting because it’s really the first time with a modern patient population that we’ve seen the outcomes of venetoclax rituximab. If you remember in the Murano study, this was a population primarily of post-chemoimmunotherapy patients. And so in contrast to the Murano study here, these patients, about 80% had prior covalent BTK inhibitors. And what we saw was a significantly shorter progression-free survival with VR in this study compared to what we’d seen previously in the Murano study. Now, it’s always difficult to compare across studies, but I think it does give us a sense that these patients with covalent BTK inhibitor progression can have quite aggressive disease and can be quite challenging to treat. And so that’s why, as I was saying before, I think that using PVR in that population post-covalent BTK inhibitor could be a particularly helpful strategy.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.